Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies ...

Q1 2025 Earnings Call Transcript April 25, 2025 Operator: Good afternoon. Welcome to the First Business Financial Services ...

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update <li /> Successful s ...

U.S. consumers could start to notice trade-related shortages in their local stores next month, according to Apollo.

These eight upstart consulting firms are specialized and have an AI-first philosophy, helping them compete with established ...

Following the presentations, each poster will be available on Connect’s website under the Presentations and Publications section.